Ovarian sex cord-stromal tumors (SCST) represent approximately 8% of ovarian cancers. They are thought to arise primarily from the sex-cord and/or stromal cells of the ovarian follicles and/or their precursor cells (1) . Malignant ovarian tumors should be viewed not as a single entity, but as a group of histologically, genetically and functionally distinct diseases, associated with the same organ, the ovary. Epithelial ovarian cancers (EOC) represent the majority of ovarian tumors, the other two primary classifications are germ cell tumors and SCST (2) . Ovarian SCST are classified histologically as granulosa cell tumors (GCT), theca-fibroma, Sertoli stromal tumors and SCST of mixed or unclassified cell type, with the sub-classifications of these groups shown in Table 1 . The most common of the malignant tumors are GCT which account for approximately 90% of malignant SCST. The clinical and molecular features of GCT have previously been reviewed by Jamieson and Fuller (2) . Although recurrent and advanced stage GCT are associated with approximately 80% mortality (2), they remain a relatively neglected subset of tumors. The high mortality rate of advanced disease is not helped by the tendency to simply group all ovarian cancers with EOC and to apply treatment regimens, based on therapeutic approaches for EOC, rather than tailored to SCST (2) . The need to understand the genetics and hence the biology of these distinct tumors therefore has an immediacy beyond just understanding the tumor biology, with targeted therapeutics urgently needed for women with SCST. In this review we will explore recent studies that provide further insights into the genetics and genomics of these tumors, and seek to identify key unanswered questions. 
Ovarian SCST: clinical, histology and functional aspects

Granulosa cell tumors
As the name implies, they arise from the granulosa cells (GC) of the ovarian follicle, which is reflected in both a response to endocrine stimuli and the synthesis of both estrogen and gonadal peptides. The former may result in inappropriate pre-pubertal or post-menopausal estrogenization while gonadal peptides such as inhibin and anti-Mullerian hormone (AMH) can be used in diagnosis and more specifically as tumor markers. The relative clinical merits of these markers has been extensively canvassed (2) . Studies from our and other laboratories examining gene expression and signaling pathways have provided compelling support that GC are indeed the cell type of origin for GCT with features consistent with proliferating GC of the early antral follicle (3) . GCT are sub-classified into juvenile (jGCT) and adult (aGCT) forms; jGCT represent approximately 5% of all GCT.
Fibromas
They are benign tumors, composed almost entirely of fibroblasts forming collagen and are the most common benign SCST, accounting for 4% of all ovarian tumors (1).
Thecomas
As the name implies, they have the appearance of theca cells or occasionally of lutein cells; they may secrete gonadal steroids.
Sertoli-Leydig cell tumors
Sertoli-Leydig cell tumors (SLCT) exhibit cellular and molecular markers consistent with a dysgenesis of the ovarian stromal cells, reminiscent of disorders of gonadal dysgenesis reviewed elsewhere in this issue of the journal.
Gynandroblastomas
They are very uncommon tumors which exhibit bidirectional differentiation, typically consisting of cells with both ovarian (GC and/or theca) and testicular (Sertoli and or Leydig) features.
The other histological types (Table 1) are very uncommon with the classification being almost exclusively histological, i.e. descriptive.
Hereditary syndromes associated with ovarian SCST
Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is associated with ovarian SCST having a histological type that is intermediate between GCT and Sertoli cell tumors (4) . In the majority of cases, PJS is caused by autosomal dominant germ line mutations in the STK11/LKB1 (serine/threonine kinase 11/liver kinase B1) gene on chromosome 19p13.3 (5, 6) . LKB1 activates AMP kinase and is commonly thought of as a tumor suppressor gene. Patients with PJS have pigmentation of the lips, buccal mucosa and digits, together with gastrointestinal hamartomata, polyposis and both benign and malignant tumors of various organs (7) . Mutations in the LKB1 gene and loss of heterozygosity (LOH) at chromosome 19p13.3 have not been found in sporadic ovarian SCST (8, 9) .
Ollier disease and Maffucci syndrome
They are rare inherited disorders characterized by enchondroma, a benign cartilaginous tumor. Juvenile GCT have been reported in association with both conditions (10) (11) (12) (13) (14) (15) (16) . While Ollier disease is associated with multiple enchondromas at multiple sites, in Maffucci syndrome these are found in association with multiple soft tissue hemangiomata (17) . Mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes have been identified in enchondroma in both Ollier disease and Maffucci syndrome (18, 19) . The mutant IDH gene produces the potential 'oncometabolite' 2-hydroxyglutarate (2-HG) which induces hypermethylation of histones in DNA (20) . The role of either the mutant IDH gene or 2-HG in the pathogenesis of jGCT is not known, but they may represent an early post-zygotic event which accounts for the initiation of the disease process (21) .
DICER1 syndrome
DICER1 syndrome results from germ-line mutations in the DICER1 gene. Dicer plays a fundamental role in processing micro(mi)RNA to their mature forms. Both germ line and somatic mutations in the DICER1 gene have been associated with ovarian SCST, predominantly SLCT. Initially reported to cause familial pleuro-pulmonary blastoma, DICER1 mutations were subsequently found in a variety of tumors, including ovarian SLCT and in association with benign thyroid pathologies (22) . Approximately 60% of ovarian Sertoli cell and SLCT harbor a DICER1 mutation which in 80% is the p.E1705K mutation (22, 23) . DICER1 mutations were also found in gynadroblastomas but they have not been associated with GCT or indeed, testicular stromal tumors (22) (23) (24) . This DICER1 mutation induces a selective reduction in RNaseIIIb activity but RNaseIIIa activity is retained which may bias the mutated DICER toward processing of the RNaseIIIa strand of the miRNA duplex (23, 25) .
Genomic changes in ovarian SCST
Studies of changes at a genomic level in ovarian SCST have largely been restricted to aGCT. In contrast to EOC, GCT have a relatively stable karyotype (26) . Cytogenetic (27) and comparative genomic hybridization (CGH) (28) studies have reported trisomy of chromosomes 12 and 14 in approximately one third of cases and monosomy of chromosome 22 in a similar percentage (27, 28) . Although between 5% and 20% of GCT are aneuploid, neither the karyotype nor ploidy provides prognostic information (27, (29) (30) (31) . A lesser frequency of mutations has been observed at other loci.
Caburet et al. (32) have recently applied CGH to a panel of aGCT. They also collated data from a total of 94 aGCT from previous studies. A total of 64 had large-scale chromosomal changes. They report supernumery chromosomes 8, 9, 12 and 14; the latter being very common (25 of 64). They also report partial or complete loss of chromosomes 1p, 13p, 16, 11 and 22, with monosomy 22 being very common (36 of 64). They found co-occurrence of chromosomal alterations but only a statistically significant non-random association for +14 with −22 and +7 with −16q. Caburet et al. (32) also combined transcriptomic data from a previous study (33) to seek to identify gene copy number changes that may reflect putative driver changes in the pathogenesis of these tumors. They identified 20 genes from the regions of chromosomal imbalance with a plausible, pathological role, across nine chromosomes (1, 5, 11, 12, (14) (15) (16) (17) 22) with the AKT1 gene being the most frequently amplified (6 of 10 tumors) and the nuclear receptor, rev-erbAα being the second most frequent (5 of 10 GCT). The later is consistent with the findings of a previous study of nuclear receptor gene expression in aGCT (34) . They also sought recurrent 'broken' genes as defined by the presence of a mapping breakpoint within the genes in two or more tumors. Five genes were identified on five different chromosomes. The authors (32) highlight the potential of these genes to drive the pathogenesis of GCT, while noting the limitation that the correlation set comprised only 10 aGCT, 9 of which were stage one.
Somatic genetics of jGCT
jGCT, as with aGCT, macroscopically exhibit a mixture of solid and cystic components with hemorrhagic areas. However, their histology differs from aGCT with a follicular or diffuse pattern of larger luteinized cells.
The cells contain hyperchromatic or markedly bizarre nuclei which lack the nuclear grooving characteristic of aGCT (2) . Although the histologic appearances are therefore more 'aggressive' than for aGCT, the prognosis is generally better. The distinction, aGCT vs jGCT, is therefore primarily based on the histology. This has created diagnostic dilemmas which are increasingly being resolved by the use of the molecular markers discussed below (24, 35, 36) . FSH stimulation of GC growth is mediated by the FSH receptor, a G-protein-coupled, seven-transmembrane domain receptor. We and others postulated that activation of these pathways, perhaps through mutations in these signaling molecules, may play a role in the pathogenesis of GCT as is seen in other endocrine tumors (2) . Despite extensive investigations, this does not appear to be the case for aGCT. However, the gsp oncogene has been observed in approximately 30% of jGCT (37) . This activating mutation of the stimulatory alpha-subunit of the hetrotrimeric G-protein (Gα s ) that couples to the seven-transmembrane domain receptors, has been reported as a somatic mutation in pituitary, thyroid and adrenal tumors as well as being the inherited mutation in the McCune-Albright syndrome (38) . In jGCT the mutation is either R201C or R201H. Kalfa et al. (37) reported that the gsp mutation was associated with a poorer prognosis. Recently Bessiere et al. (39) pursued the hypothesis that since the FSH receptor also signals through the oncoprotein AKT, mutations in this signaling pathway may be involved in the pathogenesis of jGCT. They found that >60% of jGCT have an inframe duplication that involves the plekstrin-homology domains leading to activation of AKT1; jGCT also contain AKT1 point mutations of uncertain significance. The mechanism by which this mutation activates AKT1 appears to relate to increased membrane association of the AKT1 with resulting constitutive FOXO3 repression. A subsequent study using transcriptomic analyses by the same group found that the changes in gene expression in these tumors may reflect a limited set of transcription factors altered by AKT1 activation (40) .
Somatic genetics of aGCT
In 2009 Shah et al. (26) reported that >97% of aGCT contained a specific missense mutation in the FOXL2 gene. Their approach involved a transcriptome analysis of four aGCT using massive parallel sequencing or 'RNA-Seq'. They identified a single somatic missense mutation in codon 134 (402C→G) resulting in the substitution of a highly conserved cysteine residue by tryptophan. Subsequent studies from a number of groups, including our own, (reviewed in Ref.
2) confirmed this finding. In the expanded cohort component of the study of Shah et al. (26) and in subsequent studies, both heterozygosity and hemi-homozygosity were observed. The mutation appears unique to aGCT in that it is found in neither jGCT nor in other tumor types (2) . The otherwise rare exceptions to this rule appear either to be mixed tumors in which elements are in fact of GC origin or the occasional tumor which truly is 'the exception to the rule'. In the characterization of our cohort (35), we found exceptionally high FOXL2 mRNA levels in a GCT (from an elderly women) with wild-type FOXL2 but otherwise, by all traditional clinical and histopathological criteria, an aGCT.
The presence of the FOXL2 C134W mutation provides a clear distinction between jGCT and aGCT, indeed in jGCT FOXL2 expression maybe low or absent, (35, 41) whereas in aGCT expression levels in tumors bearing the mutation are generally consistent with levels in the normal ovary (35) with expression in heterozygous tumors being equivalent for the wild-type and mutant FOXL2 alleles. In jGCT low or absent expression of FOXL2 is a feature of aggressive disease and carries a poor prognosis. The presence of the FOXL2 C134W mutation provides a molecular diagnosis of aGCT which is helpful in resolving the diagnosis of aGCT in histologically ambiguous or problematic cases (24, 35, 36) .
FOXL2 is a member of the forkhead box (FOX) family of evolutionarily conserved transcription factors. The C134W mutation is predicted to lie close to but not in the DNA-binding domain (26) . FOXL2 plays a fundamental and essential role in ovarian development; its biology has been extensively studied (42) (43) (44) . Conversely, despite an extensive understanding of the biology of FOXL2, the mechanisms of the tumorigenesis mediated by the FOXL2 C134W mutation in aGCT remain to be clearly established. There is in vitro evidence that it impacts both steroidogenesis and apoptosis in GC (44) . It is likely that post-translational modifications (sumoylation, phosphorylation, acetylation and ubiquitinylation) play a critical role in the modulation of FOXL2 function (42, 44) . Kim et al. (45) reported increased phosphorylation of FOXL2 as a result of the C134W mutation leading to ubiquitinylation and degradation. The biology is likely to reflect an impact of the mutation on critical protein-protein interactions of FOXL2 but these also remain to be clearly elucidated. Caburet et al. (42) in a detailed review of FOXL2 function and the C134W mutation argued that FOXL2 is a tumor suppressor gene with loss-of-function being associated with malignancy as is seen in jGCT and therefore that the C134W mutation compromised function rather than being associated with activation or indeed a gain of function. Conversely, others have argued that FOXL2 may be a tumor suppressor gene in jGCT but that FOXL2 C134W may be oncogenic in aGCT (43) . It is likely to be more complex than a simple loss-of-function, otherwise aGCT would surely have been identified containing other inactivating mutations of FOXL2 (2). It is perhaps reminiscent of the situation with the DICER1 mutation in SLCT where one aspect of DICER function is selectively lost (25) . It is also of course curious that aGCT express the wild-type FOXL2 allele at equivalent levels to the mutant allele, a scenario which arguably demands that the mutant FOXL2 must be 'dominant negative' if there is suppression of function.
Although the majority of aGCT are stage 1 tumors and therefore cured by surgical resection, those that present at a more advanced stage or recur, sometimes many years later, carry a poor prognosis (2) . As the FOXL2 C134W mutation is present in essentially all aGCT, it cannot explain differences in stage or behavior. It may be, as with certain inherited mutations, e.g. the ret proto-oncogene in medullary thyroid cancer (46) , that the transition from 'hyperplasia' induced by the etiologic mutation to frank malignancy requires a second independent hit; this second event may be less specific than the first. In the case of aGCT, the genomic changes described above may for instance reflect the 'second hit' that results in aggressive clonal expansion. The subsequent somatic mutations that presumably drive tumorigenesis, recurrence, aggressive behavior, transcoelomic spread and metastatic disease remain to be elucidated.
Currently the only published study of unbiased mutation detection for aGCT is the Shah et al. (26) study and that involved only four GCT. The approach taken by The Cancer Genome Atlas project (TCGA) where a defined cohort of tumors is subjected to the full gamut of genomic and genetic technologies (47) has yet to be applied to aGCT or indeed to other ovarian SCST. There have been many studies which sequence candidate genes and known oncogenes in GCT (2); these have served to exclude changes in genes commonly affected in other malignancies such as p53, PI3K, RAS and BRAF but specific, putatively 'second-hit' mutations remain to be identified.
The GCT transcriptome
Several transcriptomic studies have recently been published which identified genes whose expression has been altered; in some cases these may reflect genomic rearrangements. Benayoun et al. (33) used gene expression microarrays to compare the aforementioned 10 aGCT with two GC samples obtained during in vitro fertilisation (IVF) egg retrieval. In principal IVF should provide a ready source of 'normal' tissue to use as a control in these studies; the caveat, however, is that most IVF cycles involve a hyperstimulation regime with gonadotropin which means that at the time of retrieval the GC are partially luteinized, which is a limitation of their use as a control, because as noted earlier, aGCT appear to arise from GC in the proliferative phase (3). Benayoun et al. (33) identified upregulation of genes linked to cell proliferation and described decreased expression of genes that promote apoptosis. They also found clear evidence of regulation of genes known to be FOXL2 targets. They emphasized that genes normally down-regulated by FOXL2 but increased in this context were those associated with malignancy whereas those normally increased by FOXL2, which are associated with apoptosis, were down-regulated. They argue that the FOXL2 C134W mutation therefore causes a partial loss-of-function as seen in a tumor suppressive gene which they view as being consistent with the finding of the loss of FOXL2 expression in jGCT as discussed above (42) .
We have explored the transcriptomic profile of six stage 1 and six stage 3 aGCT to identify differences in gene expression that may contribute to advanced stage disease using a gene microarray approach (48) . As in the study of Benayoun et al. (33) , all of the aGCT studied were heterozygous for the FOXL2 C134W mutation. A total of 16 genes were identified that were more abundant in the advanced aGCT and 8 were found to be more highly expressed in the stage 1 aGCT as defined by a p value of <0.05 and more than twofold change after appropriate statistical testing to exclude false discovery. The two most prominently expressed genes in the advanced stage aGCT, CXCL14 (chemokine C-X-C-motif ligand 14) , an orphan member of the CYS-X-CYS subfamily of cytokines and MFAP5 (microfibrillar-associated protein 5 transcript variant 1) were 40-and 26-fold higher, respectively. Both have been associated with malignancy. Of the genes whose expression was high in the stage 1 aGCT, INSL3 (insulin-like 3 transcript variant 2) stood out by being 75-fold higher and provided robust discrimination of the two groups. Whether it inhibits tumorigenesis or whether the diminished expression with advanced stage disease is simply a marker of de-differentiation of the tumor remains to be determined.
Gene Set Enrichment Analysis (GSEA) of these data sets (48) identified increased expression of genes on chromosome 7p15 in the stage 3 aGCT consistent with the report of Lin et al. (28) who in a study of GCT using CGH identified gain of chromosome region 7p15-p21 in some samples. This region contains the HOXA locus providing evidence that the increased expression at this locus may be a feature of advanced disease.
The 'miRNA-ome' and other non-coding RNAs
The identification of a pathogenetic role for aberrant miRNA processing in SLCT and gynandroblastomas argues for a more general role for miRNA in SCST. Studies of the 'miRNA-ome' have, however been limited. Rosario et al. (49) have profiled miRNA expression and regulation in two human GCT-derived cell lines; they found that COV434 cells preferentially expressed miR-17 family members whereas the KGN cells preferentially expressed members of the let-7 miRNA gene family. There have not, however, been systematic studies in GCT or, to our knowledge, in other SCST.
Long non-coding (lnc) RNA's have also been implicated in oncogenesis (50) . There is a growing body of evidence that lncRNA can produce short peptides from small open reading frames (smORFs) to regulate biological processes (51) . The status of both lncRNA, and indeed, smORFs remains to be investigated in SCST.
GCT-derived cell lines
The two human GCT-derived cell lines KGN and COV434 have been used extensively in studies of GCT and indeed of GC. Both exhibit some features of normal proliferating GC including a functional follicle stimulating hormone (FSH) receptor and aromatase activity. Jamieson et al. (35) analyzed the FOXL2 status of both lines: COV434 cells lack the FOXL2 C134W mutation in their DNA and do not express FOXL2 providing compelling evidence that they are derived from a jGCT (35) . Conversely, the KGN cell line, which was established from a metastatic GCT, both expresses FOXL2 and is heterozygous for the FOXL2 mutation, consistent with it being derived from an aGCT (35) . Both are derived from advanced aggressive disease.
Both lines are notable for constitutive activation of the NFkB and Braf/ERK signaling pathways (52) (53) (54) (55) . Rosario et al. (56) used a transcriptomic approach with these cell lines to identify potential targets of FOXL2. They found many of the genes regulated by wild-type FOXL2 to be also regulated by the mutant FOXL2. Using pathway analysis they found genes in the transforming growth factor-beta (TGF-β) signaling pathway to be regulated by FOXL2 and mutant FOXL2. Their analysis also highlighted the significant differences between the jGCT-derived COV434 and the aGCT-derived KGN cells gene-expression profiles (56) . In our transcriptomic analysis of aGCT (48) we found that greater than 3000 entities differed by more than twofold at a p value of <0.05 when the 12 aGCT were compared with the KGN cells which is in stark contrast to when the stages 1 and 3 aGCT were compared with only 24 genes being identified. The two cell lines therefore, while valuable tools in the analysis of signaling pathways in the context of both GCT and indeed GC, do not greatly help in the genomic and/or genetic analysis of aGCT.
Animal models of ovarian SCST
There are a number of mouse models in which GCT arise but none truly recapitulate the human situation (2, 57). Liu et al. (57) have described the development of GCT in mice with FOXO1/3 inactivated selectively in GC; the appearance of these tumors was accelerated by PTEN deletion. They also examined five human aGCT for PTEN and FOXO1/3 expression, all of which they found to be low. They conclude that this mouse model in contrast to others shares some characteristics with aGCT. Involvement of PTEN in the model, however, is more consistent with activation of PI3K/AKT as is seen in the jGCT. It should be noted that neither mutation, over-expression of PIK3CA or PIK3R1, nor loss of expression of PTEN, has been reported in aGCT (58) . Work from Lague et al. (59) has provided evidence in mouse models for a synergistic effect of the Wnt/β-catenin and PI3K/AKT pathways in the formation of GCT which is of interest in the context of recent studies which identify a role for AKT1 mutations in jGCT. The Wnt/β-catenin signaling pathway has well established roles in ovarian development and in GC function (2) . Although dysregulation of Wnt/β-catenin signaling has been identified in many human cancers, studies in human GCT (60, 61) did not identify activation of this signaling pathway in contrast to equine GCT which have clear evidence of activation of Wnt/β-catenin signaling (60) . Increased ovarian R-spondin1 signaling, which will modulate Wnt signaling is associated with GC-like tumors (62). Gao et al. (63) targeted expression of a constitutively activated TGF-β receptor to GC and found GCT that were associated with elevated inhibin and estrogen levels as is seen in human GCT which perhaps more closely recapitulates the clinical situation than earlier models in which inhibin gene deletion resulted in GCT (64) . One of the downstream consequences of this activation is again, increased AKT signaling.
Conclusions
It is often said that rare tumors can be prismatic in the identification of molecular mechanisms in oncogenesis and the ovarian SCST are no exception. A series of recent genetic discoveries has provided profound insights into the molecular pathogenesis of ovarian SCST. The DICER1 mutation in SLCT highlights both the asymmetry and complexity of miRNA processing while also highlighting the potential for so-called 'non-coding' RNA's to play a critical role in neoplasia. The presence of the recurring gsp oncogene and the unique AKT1 mutation observed in jGCT, highlights the critical role of the cyclic AMP/protein kinase A and PI3kinase/AKT signaling pathways respectively, in hormone-mediated cell proliferation and, when constitutively activated, in malignancy. Although the FOXL2 C134W mutation would appear pathognomic for aGCT, the precise mechanism of this effect remains somewhat controversial. Other mutations, however, appear restricted to their syndromic context. These findings have provided insights into the biology of these genes and to the role they play in sex-cord stromal cell development and biology. Of critical interest to those women afflicted with these malignancies is whether this information can be translated into both prognostic information and indeed into therapeutic options; the current treatments have recently been reviewed by Foulkes et al. (65) . It is very clear that these tumors are not the same as EOC and in the age of 'precision' medicine each must be treated with a tumor-, and perhaps, mutation-specific approach. In the case of aGCT which are the most common and when advanced, carry a poor prognosis, options beyond the FOXL2 mutation are needed. The latter is likely to be difficult to target and it is clear that other genetic or genomic changes must determine late recurrence and an advanced stage. We can anticipate that with the application of whole-exome sequencing, RNA-seq and perhaps interrogation of the miRNA-ome that critical driver mutations will be found for GCT and indeed the other SCST that are 'actionable mutations'.
